Portal de Periódicos da CAPES

Cardiovascular Events in Systemic Lupus Erythematosus

2015; Wolters Kluwer; Volume: 94; Issue: 29 Linguagem: Inglês

10.1097/md.0000000000001183

1536-5964

Antonio Fernández‐Nebro, Íñigo Rúa‐Figueroa, Francisco Javier López-Longo, María Galindo, Jaime Calvo‐Alén, Alejandro Olivé-Marqués, Carmen Ordóñez-Cañizares, María A. Martín‐Martínez, Ricardo Blanco, R. González, J. Ibáñez-Ruán, J. A. Bernal, Eva Tomero-Muriel, Esther Uriarte-Isacelaya, Loreto Horcada-Rubio, Mercedes Freire-González, Javier Narváez, Alina Boteanu, G. Santos-Soler, José Luís Andreu, José María Pego‐Reigosa,

Monoclonal and Polyclonal Antibodies Research

This article estimates the frequency of cardiovascular (CV) events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus (SLE) and investigates the main risk factors for atherosclerosis. RELESSER is a nationwide multicenter, hospital-based registry of SLE patients. This is a cross-sectional study. Demographic and clinical variables, the presence of traditional risk factors, and CV events were collected. A CV event was defined as a myocardial infarction, angina, stroke, and/or peripheral artery disease. Multiple logistic regression analysis was performed to investigate the possible risk factors for atherosclerosis. From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374 (10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the CV events occurred after SLE diagnosis (86.2% women, median [interquartile range] age 54.9 years [43.2-66.1], and SLE duration of 212.0 months [120.8-289.0]). Strokes (5.7%) were the most frequent CV event, followed by ischemic heart disease (3.8%) and peripheral artery disease (2.2%). Multivariate analysis identified age (odds ratio [95% confidence interval], 1.03 [1.02-1.04]), hypertension (1.71 [1.20-2.44]), smoking (1.48 [1.06-2.07]), diabetes (2.2 [1.32-3.74]), dyslipidemia (2.18 [1.54-3.09]), neurolupus (2.42 [1.56-3.75]), valvulopathy (2.44 [1.34-4.26]), serositis (1.54 [1.09-2.18]), antiphospholipid antibodies (1.57 [1.13-2.17]), low complement (1.81 [1.12-2.93]), and azathioprine (1.47 [1.04-2.07]) as risk factors for CV events. We have confirmed that SLE patients suffer a high prevalence of premature CV disease. Both traditional and nontraditional risk factors contribute to this higher prevalence. Although it needs to be verified with future studies, our study also shows-for the first time-an association between diabetes and CV events in SLE patients.